Our top pick for
Trevena Inc is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 25 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.11|
|52-week range||$1.09 - $3.10|
|50-day moving average||$1.24|
|200-day moving average||$1.55|
|Wall St. target price||$5.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.31%|
|1 month (2021-09-21)||-9.02%|
|3 months (2021-07-21)||-30.63%|
|6 months (2021-04-21)||-36.57%|
|1 year (2020-10-20)||-60.07%|
|2 years (2019-10-18)||19.35%|
|3 years (2018-10-19)||34.77%|
|5 years (2016-10-20)||5.9|
|Revenue TTM||$3.5 million|
|Gross profit TTM||$2.9 million|
|Return on assets TTM||-29.1%|
|Return on equity TTM||-56.62%|
|Market capitalisation||$187.5 million|
TTM: trailing 12 months
There are currently 14.2 million Trevena shares held short by investors – that's known as Trevena's "short interest". This figure is 3.4% down from 14.7 million last month.
There are a few different ways that this level of interest in shorting Trevena shares can be evaluated.
Trevena's "short interest ratio" (SIR) is the quantity of Trevena shares currently shorted divided by the average quantity of Trevena shares traded daily (recently around 918619.93527508). Trevena's SIR currently stands at 15.45. In other words for every 100,000 Trevena shares traded daily on the market, roughly 15450 shares are currently held short.
However Trevena's short interest can also be evaluated against the total number of Trevena shares, or, against the total number of tradable Trevena shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevena's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Trevena shares in existence, roughly 90 shares are currently held short) or 0.0871% of the tradable shares (for every 100,000 tradable Trevena shares, roughly 87 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Trevena.
Find out more about how you can short Trevena stock.
We're not expecting Trevena to pay a dividend over the next 12 months.
Over the last 12 months, Trevena's shares have ranged in value from as little as $1.091 up to $3.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.4058. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.